Skip to main content
GoodMoatv1.3
Sign in
CAPR logo

CAPR

CompareEarnings: Aug 31, 2026

Capricor Therapeutics Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Capricor Therapeutics, Inc. is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need.

Current Price

$29.58

+1.96%
Profile
Valuation (TTM)
Market Cap$1.70B
P/E-14.85
EV—
P/B5.56
Shares Out57.51M
P/Sales—
Revenue$0.00
EV/EBITDA—

Capricor Therapeutics Inc (CAPR) Company Profile

CAPR Company Information

Capricor Therapeutics, Inc. is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy.

Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease.

Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy.

Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

California, USA

CAPR Key Officers

Key officers data coming soon

CAPR Company Profile

Capricor Therapeutics Inc (CAPR) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in California, USA.

Capricor Therapeutics, Inc. is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need.

Market cap is $1.70B. There are 57.5M shares outstanding.

See the full Capricor Therapeutics Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if CAPR is a good investment.